This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix receives FDA warning letter regarding ReSure Sealant

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has issued a warning letter to Ocular Therapeutix regarding the company’s compliance with data collection and information reporting obligations related to the premarket approval application for ReSure Sealant, according to a company press release.

Ocular Therapeutix is required to provide periodic reports on the progress of a post-approval Device Exposure Registry study as a condition for approval.

The company is “committed to working with the FDA to address and resolve the concerns cited in the warning letter” and intends to respond within the required 15 days, the company stated in the release.